Free tool
FAERS Monitor: Zypitamag
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208379 or its brand name (Zypitamag, Pitavastatin Magnesium). Reports on generic versions are filed under their own applications.
Reports
59
Serious
28
47% of reports
Hospitalization
11
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache6
- death5
- dyspnoea5
- hospitalisation5
- product dose omission issue5
- pruritus5
- pain4
- arthralgia3
- cardiac death3
- constipation3
- dizziness3
- fall3
- fatigue3
- malaise3
- muscle spasms3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 9 |
| 2022 | 22 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,100 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cardiac deathSignal | 3 | 888.4 | 294.6 | 1,841 |
| hospitalisationSignal | 5 | 11.6 | 5.0 | 39 |
| product dose omission issueSignal | 5 | 6.1 | 2.6 | 17 |
| muscle spasmsSignal | 3 | 5.8 | 1.9 | 8 |
| constipationSignal | 3 | 4.9 | 1.6 | 6 |
| pruritusSignal | 5 | 4.6 | 2.0 | 11 |
| headacheSignal | 6 | 3.4 | 1.6 | 8 |
| fall | 3 | 3.2 | 1.1 | 3 |
| dyspnoeaSignal | 5 | 3.1 | 1.4 | 5 |
| arthralgia | 3 | 2.6 | 0.9 | 2 |
| malaise | 3 | 2.4 | 0.8 | 1 |
| pain | 4 | 2.3 | 0.9 | 2 |
| dizziness | 3 | 2.1 | 0.7 | 1 |
| death | 5 | 2.1 | 0.9 | 2 |
| fatigue | 3 | 1.4 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.